RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication
Artículo científico (JournalArticle)
Biomechanical mapping of tumor growth: A novel method to quantify glioma infiltration and mass effect
[EN] Background: Glioblastoma (GBM) growth can alter surrounding brain tissue through location-dependent physiological changes. Two main growth phenotypes¿(I) infiltrative, characterized by diffuse invasion with minimal mass effect, and (II) proliferative, characterized by pronounced tissue compression¿are recognized, but their quantitative characterization and prognostic impact remain poorly explored. Purpose: To develop and validate a novel MRI-based biomarker, the Dynamic Infiltration Rate (DIR), that quantitatively assesses the balance between tumor volume expansion and peritumoral compression, and to evaluate its prognostic ability for stratifying patients based on overall survival (OS). Methods: The DIR was defined as the ratio between tumor-volume enlargement and mass-effect-induced peritumoral compression. Technical validation was conducted using synthetic datasets with known ground truth spanning realistic infiltrative-proliferative spectra. Clinically, patients were dichotomized into high- and low-infiltration groups using a threshold optimized by maximizing the log-rank statistic for OS. Prognostic evaluation included multivariate Cox regression adjusted for age, sex, and MGMT methylation status. Results: The synthetic dataset validation demonstrated high concordance with ground truth (R² = 0.89). Clinical evaluation indicated significantly improved OS in the low DIR group (median = 35.2 weeks) compared to the high DIR group (median = 16.0 weeks; p = 0.0001). DIR effectively stratified patients based on survival (log-rank p < 0.001, HR = 2.49) and remained an independent prognostic factor on multivariate analysis (HR = 1.45, 95% CI 1.07¿1.85; p = 0.0159). Conclusions: The DIR is a novel and robust quantitative MRI biomarker capable of distinguishing between proliferative and infiltrative GBM phenotypes, independently predicting OS. Early phenotype identification could facilitate personalized treatment strategies and individualized follow-up scheduling., MCIN/AEI (Ministerio de Ciencia, Innovación y Universidades / Agencia Estatal de Investigación), Grant/Award Numbers: PID2024156848OB-I00, PID2021-127110OA-I00, PDC2025-165365-I00, FPU23/02431; Generalitat Valenciana, Grant/Award Numbers: INVEST/2022/298 (ProgramaINVESTIGO), CIAICO/2022/064(Lalaby-Glio), INNEST/2022/87(SINUÉ); European
Research Council, Grant/Award Numbers: 758657-ImPRESS, 101213953-CHRONOS; Helse Sør-Øst RHF, Grant/Award Numbers:
2021057, 2017073, 2023050; Research Council of Norway, Grant/Award Numbers: 325971, 261984, 303249, 32543, 356066;
Norwegian Cancer Society, Grant/Award Number: 309012 - SAFARI; Universitat Politècnica de València, Grant/Award Number:
PAID-01-24(Subprogram1)
Project:
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-127110OA-I00
,
European Commission / H2020 758657
,
Agencia Estatal de Investigación PID2024-156848OB-I00
,
CIENCIA INNOV. UNIV. FPU23/02431
,
Generalitat Valenciana INVEST/2022/298
,
Generalitat Valenciana CIAICO/2022/064
,
AGENCIA VALENCIANA DE LA INNOVACION INNEST/2022/87
,
Norges forskningsråd 261984
,
Norges forskningsråd 309012
,
Norges forskningsråd 325971
,
Norges forskningsråd 303249
,
Norges forskningsråd 356066
,
Universitat Politècnica de València PAID-01-24
,
European Commission 101213953
,
Agencia Estatal de Investigación PDC2025-165365-I00
,
South-Eastern Norway Regional Health Authority 2021057
,
South-Eastern Norway Regional Health Authority 2017073
,
Southern and Eastern Norway Regional Health Authority 2023050